Hypercoagulability Biomarkers in a New Score Linked to Treatment Resistance for Multiple Myeloma Patients. the Roadmap-MM Study

被引：0
|
作者：
Papageorgiou, Loula [1 ,2 ]
Fotiou, Despina [3 ]
Van Dreden, Patrick [4 ]
Garderet, Laurent [5 ,6 ]
Dimopoulos, Meletios A. [3 ,7 ]
Elalamy, Ismail [8 ]
Mohty, Mohamad [9 ,10 ,11 ]
Gerotziafas, Grigoris [12 ,13 ]
机构：
[1] Univ Pierre & Marie Curie UPMC, Paris Fac Med Pierre & Marie Curie, Inst Univ Cancerol IUC, Sorbonne Univ,Canc Biol & Therapeut,INSERM U938, Paris, France
[2] Tenon Univ Hosp, AP HP, Dept Haematol, Paris, France
[3] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece
[4] Stago, Clin Res, Gennevilliers, France
[5] Hop Pitie Salpetiere, AP HP, Serv Hematol, Paris, France
[6] Hop St Antoine, Ctr Rech St Antoine, Team Proliferat & Differentiat Stem Cells, Paris, France
[7] Univ Athens, Dept Clin Therapeut, Sch Med, Athens, Greece
[8] Paris 6 Univ, AP HP, Paris 20, France
[9] St Antoine Hosp, Dept Haematol, INSERM UMR 938, Paris, France
[10] St Antoine Hosp, EBMT Paris Study Off CEREST TC, INSERM UMR 938, Paris, France
[11] Univ Paris 06, Paris, France
[12] Sorbonne Univ, Inst Univ Cancerol, INSERM, Canc Haemostasis & Angiogenesis Res Grp, Paris, France
[13] Hop Tenon, AP HP, Thrombosis Ctr, Serv Hematol Biol, Paris, France
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-126954
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1913
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Partially T-Cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: A prospective evaluation of patients treated in the phase III study HOVON 24 MM
    Lokhorst, HM
    Segeren, CM
    Verdonck, LF
    van der Holt, B
    Raymakers, R
    van Oers, MHJ
    Barge, RMY
    Schouten, HC
    Westveer, PHM
    Steijaert, MMC
    Cornelissen, JJ
    Sonneveld, P
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (09) : 1728 - 1733
  • [42] Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study
    Fotiou, Despina
    Sergentanis, Theodoros N.
    Papageorgiou, Loula
    Stamatelopoulos, Kimon
    Gavriatopoulou, Maria
    Kastritis, Efstathios
    Psaltopoulou, Theodora
    Salta, Stella
    Van Dreden, Patrick
    Sangare, Rabiatou
    Larsen, Annette K.
    Terpos, Evangelos
    Elalamy, Ismail
    Dimopoulos, Meletios A.
    Gerotziafas, Grigoris T.
    BLOOD CANCER JOURNAL, 2018, 8
  • [43] Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study
    Despina Fotiou
    Theodoros N. Sergentanis
    Loula Papageorgiou
    Kimon Stamatelopoulos
    Maria Gavriatopoulou
    Efstathios Kastritis
    Theodora Psaltopoulou
    Stella Salta
    Patrick Van Dreden
    Rabiatou Sangare
    Annette K. Larsen
    Evangelos Terpos
    Ismail Elalamy
    Meletios A. Dimopoulos
    Grigoris T. Gerotziafas
    Blood Cancer Journal, 8
  • [44] A phase I study of lenalidomide with pioglitazone, dexamethasone and low-dose treosulfan: Combined anti-inflammatory, immunomodulatory and angiostatic treatment as third-line therapy for patients (pts) suffering from multiple myeloma (MM)
    Reichle, A.
    Vogelhuber, M.
    Kreuser, E. -D.
    Wilke, J.
    Wagner, H.
    Straka, C.
    Pronath, A.
    Andreesen, R.
    ONKOLOGIE, 2011, 34 : 160 - 160
  • [45] Initial and Confirmation Analyses of a Detailed Comorbidity and Organ Function Assessment In 593 Multiple Myeloma (MM) patients (pts) Identify the Freiburger Comorbidity Index (FCI) as a Non-Weighted, Simple, Concise and Cost Effective Comorbidity Score Consisting of 3 Factors Only: Proposal of a Valuable New Tool In MM-Risk Assessment
    Tertiorst, Meike
    Kleber, Martina
    De Pasquale, David
    Ihorst, Gabriele
    Engelhardt, Monika
    BLOOD, 2010, 116 (21) : 792 - 793
  • [46] Multicenter Open Label Phase 3 Benefit Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients. IFM2020-05
    Bobin, Arthur
    Hulin, Cyrille
    Lambert, Jerome
    Perrot, Aurore
    Manier, Salomon
    Montes, Lydia
    Jaccard, Arnaud
    Karlin, Lionel
    Godmer, Pascal
    Caillot, Denis
    Chalopin, Thomas
    Roul, Christophe
    Mariette, Clara
    Rigaudeau, Sophie
    Delaunay, Jacques
    Dingremont, Claire
    Santagostino, Alberto
    Dib, Mamoun
    Macro, Margaret
    Tiab, Mourad
    Laribi, Kamel
    Petit, Emmanuelle Bourgeois
    Calmettes, Claire
    Piocelle, Frederique Orsini
    Bareau, Benoit
    Tabrizi, Reza
    Vincent, Laure
    Mohty, Mohamad
    Touzeau, Cyrille
    Corre, Jill
    Moreau, Philippe
    Facon, Thierry
    Loiseau, Herve Avet
    Leleu, Xavier
    BLOOD, 2023, 142
  • [47] Performance of PET/CT using [18F]Fludarabine for initial staging and therapeutic evaluation of symptomatic multiple myeloma (MM) patients in first line treatment or first relapse : preliminary results of an exploratory multicenter phase 2 study
    Francois, C.
    Santiago-Ribeiro, M.
    Jamet, B.
    Guillouet, S.
    Perrio, C.
    Abbas, A.
    Gourand, F.
    Querellou, S.
    Chalopin, T.
    Dubegny, C.
    Touzeau, C.
    Blin, N.
    Kraeber-Bodere, F.
    Bodet-Milin, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S46 - S47
  • [48] TREATMENT WITH DOSE/SCHEDULE-ADJUSTED RD-R vs CONTINUOUS RD IN ELDERLY INTERMEDIATE-FIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: RESULTS OF RV-MM-PI-0752 PHASE III RANDOMIZED STUDY
    Larocca, A.
    Salvini, M.
    Gaidano, G.
    Cascavilla, N.
    Benevolo, G.
    Galli, M.
    Montefusco, V.
    Caravita, T.
    Monaco, F.
    Capra, A.
    Giuliani, N.
    Gazzera, G.
    Pulini, S.
    Ronconi, S.
    Pescosta, N.
    Liberati, A. M.
    Patriarca, F.
    Cellini, C.
    Tosi, P.
    Offidani, M.
    Cavo, M.
    Boccadoro, M.
    Bringhen, S.
    HAEMATOLOGICA, 2019, 104 : 10 - 10
  • [49] Maintenance treatment after autologous peripheral blood stem cell transplantation (PBSCT) in multiple myeloma (MM) with a unique weekly dose of pegylated interpheron alpha2b (Pegintron®):: Preliminary clinical results in 30 patients of a phase II multicentric study
    Alegre, Adrian
    Aguado, B.
    Garcia-Larana, J.
    Lahuerta, J. J.
    Mateos, M. V.
    Rodriguez-Notario, R.
    Navas, B.
    Fernandez-Ranada, J. M.
    San Miguel, J. F.
    BLOOD, 2007, 110 (11) : 279B - 280B
  • [50] Analysis of Patient (Pt) Outcomes By Prior Treatment and Depth of Response in Stratus (MM-010), a Phase 3b Study of Pomalidomide plus Low-Dose Dexamethasone (POM plus LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
    Moreau, Philippe
    Palumbo, Antonio
    Corradini, Paolo
    Cavo, Michele
    Delforge, Michel
    Weisel, Katja C.
    Ocio, Enrique M.
    Cafro, Annamaria
    Rollig, Christoph
    Knop, Stefan
    de Arriba, Felipe
    Simcock, Mathew
    Miller, Neil
    Slaughter, Ana
    Watkins, Latisha
    Herring, Jennifer
    Biyukov, Tsvetan
    Peluso, Teresa
    Zaki, Mohamed H.
    Dimopoulos, Meletios A.
    BLOOD, 2015, 126 (23)
12345